RBI
VKTX icon

Raiffeisen Bank International’s Viking Therapeutics VKTX Stock Holding History

Raiffeisen Bank International’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Hold
26,000
– – 0.01% 410
2026
Q1 		$778K Hold
26,000
– – 0.01% 410
2025
Q4 		$918K Hold
26,000
– – 0.01% 362
2025
Q3 		$671K Hold
26,000
– – 0.01% 394
2025
Q2 		$704K Buy
26,000
+1,000
+4% +$26.3K 0.01% 321
2025
Q1 		$641K Buy
25,000
+13,000
+108% +$411K 0.01% 334
2024
Q4 		$477K Buy
+12,000
New +$684K 0.01% 363

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Raiffeisen Bank International's VKTX Position: Q2 2026 in Review

Raiffeisen Bank International held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 26,000 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #410.

Raiffeisen Bank International first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Raiffeisen Bank International held 26,000 shares of Viking Therapeutics worth $1.03M as of Q2 2026.
  • Raiffeisen Bank International left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.01% of Raiffeisen Bank International's portfolio in Q2 2026, its #410 holding.
  • Raiffeisen Bank International first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.